Janumet Pancreatic Cancer

Are you a victim of Janumet pancreatic cancer? If you or a family member received a cancer diagnosis after taking the type 2 diabetes drug, Janumet, investigate your potential claim against the drugmaker by speaking with an experienced pharmaceutical lawyer now.

What is Janumet?

Janumet is the first prescription combination medication containing the active drugs sitagliptin and metformin. Both sitagliptin, a DPP-4 inhibitor first sold under the brand name Januvia, and metformin, a glucose lowering agent in a class of drugs called biguanides, are among several drugs on the market used to help control blood sugar levels in type 2 diabetics.

Manufactured by Merck, Janumet received approval by the U.S. Food and Drug Administration (FDA) in 2007 as an adjunct to diet and exercise for adult type 2 diabetics. The FDA approved the new drug based on clinical data for each of the two separate active drugs, sitagliptin and metformin. Janumet is taken twice daily with meals.

FDA Investigates Janumet Pancreatic Cancer Risk

As a sitagliptin, Janumet may increase a patient’s risk for developing cancer. Studies have shown an increased risk for various types of cancer, including pancreatic cancer, in diabetics taking sitagliptin. Read about sitagliptin and cancer here.

In March 2013 the FDA announced an investigation into a possible increased risk for pancreatic cancer in type 2 diabetics using incretin mimetic drugs. Janumet and other sitagliptin brands ( Januvia, Janumet XR and Juvisync ) are within this class of drugs.

In its investigation, the FDA is reviewing new findings by a group of academic researchers suggesting type 2 diabetics treated with incretin mimetics are at an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia. The FDA warned about a risk of acute pancreatitis associated with sitagliptin in 2009.

Risk factors for pancreatitis can also be risk factors for pancreatic cancer. Type 2 diabetics may already be at risk for developing pancreatic cancer. Now many of them take a drug that inhibits DPP-4, one of the body’s natural cancer suppressing mechanisms, and potentially increases the risk of pancreatic cancer – unaware of the increased risk.

Janumet Lawsuit

If you are considering a Janumet lawsuit, you will need a lawyer with experience successful handling injury and wrongful death claims against a large pharmaceutical manufacturer. Many injury and product liability lawyers do not have that experience.

The mass torts law firm of Watts Guerra LLP is handling the country’s largest incretins pancreatic cancer injury and wrongful death docket. The firm’s lawyers have handled hundreds of thousands of mass action claims and won some of the most significant legal victories in America.

Our highly experienced trial lawyers are reviewing claims on a national basis. Let us help you and your family.

Disclaimer: The images on this page of the Januvia packaging, product, and/or logo are for informational purposes; this website is neither affiliated with nor sponsored, endorsed, or approved by Merck & Co., Inc.

Free Case Evaluation

Disclaimer | Privacy Policy

Bookmark and Share

Mikal C. Watts

Mikal C. Watts Mikal C. Watts is one of the most successful pharmaceutical lawyers in the country. He has handled many mass torts, including Ortho-Evra, Vioxx, Fen Phen, Rezulin, Zyprexa, and Sulzer hip implants. Mr. Watts leads a team of successful trial lawyers who handle pharmaceutical product liability cases across the country.
Contact us using our online form, or call us toll-free at 1(800)796-9605.